(0.34%) 5 117.36 points
(0.34%) 38 370 points
(0.39%) 15 990 points
(-0.94%) $83.06
(5.36%) $2.03
(0.34%) $2 355.10
(0.53%) $27.68
(4.10%) $959.90
(-0.27%) $0.932
(-0.45%) $10.98
(-0.58%) $0.796
(1.66%) $93.40
3 days till quarter result
(bmo 2024-05-02)
Expected move: +/- 5.42%
@ $45.58
発行日: 15 2月 2024 @ 05:47
リターン: -0.74%
前回のシグナル: 2月 14 - 23:30
前回のシグナル:
リターン: 2.09 %
Live Chart Being Loaded With Signals
Ultragenyx Pharmaceutical Inc., a biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of novel products for the treatment of rare and ultra-rare genetic diseases in North America, Europe, and internationally...
Stats | |
---|---|
本日の出来高 | 272 083 |
平均出来高 | 696 204 |
時価総額 | 3.72B |
EPS | $0 ( 2024-02-15 ) |
次の収益日 | ( $-1.730 ) 2024-05-02 |
Last Dividend | $0 ( N/A ) |
Next Dividend | $0 ( N/A ) |
P/E | -5.48 |
ATR14 | $0.0330 (0.07%) |
Date | Person | Action | Amount | type |
---|---|---|---|---|
2024-04-18 | Crombez Eric | Sell | 142 | Common Stock |
2024-04-16 | Huizenga Theodore Alan | Sell | 14 | Common Stock |
2024-03-11 | Kassberg Thomas Richard | Sell | 11 509 | Common Stock |
2024-03-07 | Fust Matthew K | Sell | 2 550 | Common Stock |
2024-03-07 | Fust Matthew K | Sell | 2 145 | Common Stock |
INSIDER POWER |
---|
45.65 |
Last 99 transactions |
Buy: 915 632 | Sell: 371 334 |
ボリューム 相関
Ultragenyx Pharmaceutical 相関
10 最も正の相関 | |
---|---|
GAINL | 0.862 |
ITMR | 0.852 |
DVCR | 0.847 |
AVEO | 0.845 |
ISNS | 0.842 |
VLYPP | 0.831 |
CHMA | 0.825 |
OPNT | 0.825 |
SUMR | 0.813 |
EDUT | 0.813 |
10 最も負の相関 | |
---|---|
SHSP | -0.9 |
BOCH | -0.891 |
XFOR | -0.833 |
GRCL | -0.833 |
ENPH | -0.827 |
RDHL | -0.82 |
THTX | -0.819 |
PTPI | -0.805 |
QTEK | -0.801 |
BLU | -0.801 |
知っていましたか?
相関は、2つの変数間の関係を説明する統計的指標です。相関係数は-1から1までの値を取り、-1は完全な負の相関(1つの変数が増加すると、もう一方は減少する)、1は完全な正の相関(1つの変数が増加すると、もう一方も増加する)、0は相関がないことを示します(変数間に関係がない)。
相関は、株式だけでなく、どの2つの変数間の関係にも適用できます。これは、金融、経済学、心理学などの分野で一般的に使用されています。
Ultragenyx Pharmaceutical 相関 - 通貨/商品
Ultragenyx Pharmaceutical 財務諸表
Annual | 2023 |
収益: | $434.25M |
総利益: | $389.04M (89.59 %) |
EPS: | $-8.25 |
FY | 2023 |
収益: | $434.25M |
総利益: | $389.04M (89.59 %) |
EPS: | $-8.25 |
FY | 2022 |
収益: | $363.33M |
総利益: | $335.01M (92.21 %) |
EPS: | $-10.12 |
FY | 2021 |
収益: | $351.41M |
総利益: | $335.40M (95.44 %) |
EPS: | $-6.70 |
Financial Reports:
No articles found.
Ultragenyx Pharmaceutical
Ultragenyx Pharmaceutical Inc., a biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of novel products for the treatment of rare and ultra-rare genetic diseases in North America, Europe, and internationally. Its biologic products include Crysvita (burosumab), an antibody targeting fibroblast growth factor 23 for the treatment of X-linked hypophosphatemia, as well as tumor-induced osteomalacia; Mepsevii, an enzyme replacement therapy for the treatment of children and adults with Mucopolysaccharidosis VII; Dojolvi for treating long-chain fatty acid oxidation disorders; and Evkeeza (evinacumab) for the treatment of homozygous familial hypercholesterolemia. The company's products candidatures include DTX401, an adeno-associated virus 8 (AAV8) gene therapy clinical candidate for the treatment of patients with glycogen storage disease type Ia; DTX301, an AAV8 gene therapy for the treatment of patients with ornithine transcarbamylase; UX143, a human monoclonal antibody for the treatment of osteogenesis imperfecta; GTX-102, an antisense oligonucleotide for the treatment of Angelman syndrome; UX701, for the treatment of Wilson disease; and UX053 for the treatment of glycogen storage disease type III. Ultragenyx Pharmaceutical Inc. has collaboration and license agreement with Kyowa Kirin Co., Ltd.; Saint Louis University; Baylor Research Institute; REGENXBIO Inc.; Bayer Healthcare LLC; GeneTx; Mereo; University of Pennsylvania; Arcturus Therapeutics Holdings Inc., Solid Biosciences Inc.; and Daiichi Sankyo Co., Ltd. Ultragenyx Pharmaceutical Inc. was incorporated in 2010 and is headquartered in Novato, California.
について ライブシグナル
このページで提示されるライブシグナルは、NA を買う時や売る時を判断するのに役立ちます。シグナルには1分以上の遅延があります。市場シグナルには誤りやミスの可能性があるため、ライブ取引シグナルは決定的ではなく、getagraph.comはこれらのシグナルに基づく任意の行動について責任を負いません。詳細については、利用規約で説明されているように、技術分析指標に基づいています。